Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELAM02: IL-2 Maintenance in Pediatric AML
NCT00149162Phase 3Unknown
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2005
- Primary completion
- Dec 2010
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 3 trial of aldesleukin in acute myeloid leukemia (AML), sponsored by Assistance publique - Hôpitaux de Paris. Status: unknown.
02
Drugs
aldesleukin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00149162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00149162.